MarketScreener’s Digital Health and Telemedicine Stock Theme
MarketScreener is presenting a thematic stock selection designed for investors who want exposure to digital health and telemedicine. The theme bundles companies that connect doctors and patients digitally, collect and analyse medical data — including through artificial intelligence and cloud-based platforms — and make health devices that automatically send results to patients.
The central market claim is that global telemedicine will climb from $75 billion in 2022 to $200 billion by 2027. That is roughly a 2.7-fold increase over five years, implying a compound annual growth rate of about 22 percent.
The growth case rests on two demand drivers. First, more than half of the world's population still lacks access to basic health services; as underserved markets gain broadband access, telemedicine is positioned to close part of that gap. Second, the pandemic and post-pandemic period made many people try remote care for the first time, which MarketScreener argues accelerated acceptance of digital health services.
The selection itself sits behind MarketScreener's subscription tools, so investors receive the company names only after subscribing. The public material explains the theme but does not disclose the specific holdings or selection methodology.
The Growth Arithmetic and Risk Mix Behind the $200bn Telemedicine Forecast
Why the $200bn Target Demands Aggressive Execution
Going from $75bn to $200bn in five years is not a modest progression. The implied compound annual growth rate is close to 22 percent, meaning the market would need to add about $25bn in annual revenue on average each year. That is possible only if broadband expansion, reimbursement systems and clinical acceptance move together. The headline number is a market-sizing assumption, not a company-level earnings forecast.
The Theme Mixes Three Different Business Models
The selection includes digital doctor-patient services, medical data and AI analytics platforms, and connected health devices. These are not interchangeable risk profiles: a cloud analytics provider faces data protection and regulatory hurdles, while a connected device maker depends on hardware adoption and distribution. Investors looking at the theme should judge each segment on its own economics rather than treating digital health as one uniform market.
The Pandemic Effect Is Real but Not Automatically Recurring
First-time pandemic users expand the potential user base and can normalise remote consultations. But the source material does not show repeat-usage data or whether providers converted emergency demand into ongoing subscriptions. The strongest investment case would be companies that can show recurring revenue from remote care, not simply a temporary jump in consultations.
What Investors Should Check Before Buying the Digital Health Theme
Because the piece describes a theme rather than a specific stock list, the practical use is as a screening framework:
- Map any candidate to the three segments the theme describes — doctor–patient connectivity, AI and cloud-based medical data analysis, and connected health devices — and ask whether the company has a defensible position in at least one, rather than only a thematic label.
- Use the 2022–2027 jump from $75bn to $200bn as a sizing check. At an implied compound annual growth rate of about 22 percent, current valuations already have to price in aggressive expansion, so earnings delivery matters more than the headline forecast.
- Look for evidence that demand in under-served markets is becoming paying demand — especially broadband availability, local payment rules and reimbursement — because the access gap only becomes telemedicine revenue if those conditions are met.
- Separate pandemic-driven trial use from durable adoption; prefer companies that show repeat consultations, recurring subscriptions or long-term contracts rather than one-off surge volumes.
Risk & Opportunity Assessment
| Commercial Risk | Medium | The $75bn to $200bn forecast implies roughly 22% compound annual growth; if adoption in under-served markets is slower than projected, revenue growth may fall well short of the market-sizing assumption. |
| Competitive Risk | Medium | The theme spans three separate segments — digital doctor-patient services, AI/cloud data analytics, and connected health devices — each with multiple providers, and the promotional material names no specific companies, so differentiation is unproven. |
| Regulatory Risk | Medium | Because the theme explicitly includes companies that collect, store and analyse medical data with AI and cloud platforms, health-data privacy rules are a direct exposure even though the material does not address them. |
| Reputation Risk | Low | Reputation risk is limited at the theme level, but a failure to convert first-time pandemic users into repeat patients could weaken the acceptance narrative that underpins the growth case. |
| Technology Disruption | High | The theme depends on cloud computing, artificial intelligence and connected devices, meaning the technology itself is the product; new platforms or device makers can quickly erode existing advantages. |
| Commercial Opportunity | High | More than half the world's population still lacks basic health services, and broadband expansion in underserved markets could create a large new customer base for digital health and telemedicine companies. |
Comments 0